Dr. Snigdha Nutalapati, MD

Dr. Nutalapati practices at Ephraim McDowell Regional Medical Center in Danville, Kentucky, part of Ephraim McDowell Health.

Dr. Nutalapati's NPI, 1912350042, was assigned on July 13, 2016. Dr. Nutalapati holds Kentucky license 52802.

Dr. Nutalapati's primary practice is Ephraim McDowell Regional Medical Center, at 217 South Third Street, Danville, KY 40422 in Boyle County. The practice phone is (859) 239-1000.

Dr. Nutalapati's primary practice is Ephraim McDowell Regional Medical Center in Danville, Kentucky, part of Ephraim McDowell Health. Dr. Nutalapati is also affiliated with Select Specialty Hospital - Central Kentucky. The medical group on file is Ephraim McDowell Regional Medical Center. Dmand AI also links Dr. Nutalapati to 4 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nutalapati practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Nutalapati's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Nutalapati is licensed in Kentucky.

CMS data shows 273 Medicare services from Dr. Nutalapati across 3 procedure codes in 2024, all of them office visits, for 86 Medicare patients. Medicare paid $30,695 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 86 Medicare patients who saw Dr. Nutalapati in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 26% are also on Medicaid. Their average risk score is 2.39, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nutalapati's median patient age at 72, with 58% women.

In 2024, Dr. Nutalapati wrote 811 Medicare Part D claims for 106 patients. 84% of them were for generic drugs. CMS names the drug for 572 of them, across 20 drugs with 11 or more claims each, at $681,816 in total drug cost. In 2023, CMS named 302 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Nutalapati for performance year 2024, reported as part of a group. Dr. Nutalapati accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Nutalapati, published from 2018 to 2024. 2021 was the busiest year, with 3. The most frequent topics are Black or African American. Dr. Nutalapati's most frequent co-authors are Marilyn G. Foreman, MD, Gerhard Carl Hildebrandt, MD and Mautin Temitope Barry-Hundeyin, MD.

CMS Open Payments shows 15 general payments to Dr. Nutalapati from 11 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 91% of the total. Tempus AI, Inc paid the most, $187.